MARKET

NBIX

NBIX

Neurocrine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

110.85
+0.08
+0.07%
After Hours: 110.85 0 0.00% 17:26 11/11 EST
OPEN
109.86
PREV CLOSE
110.77
HIGH
112.37
LOW
108.99
VOLUME
1.00M
TURNOVER
--
52 WEEK HIGH
112.37
52 WEEK LOW
64.72
MARKET CAP
10.21B
P/E (TTM)
656.31
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NBIX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 19 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NBIX News

  • Edited Transcript of NBIX earnings conference call or presentation 4-Nov-19 9:30pm GMT
  • Thomson Reuters StreetEvents.2d ago
  • Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
  • PR Newswire.6d ago
  • Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $122
  • Benzinga.6d ago
  • Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.6d ago

More

Industry

Biotechnology & Medical Research
-0.51%
Pharmaceuticals & Medical Research
-0.43%

Hot Stocks

Name
Price
%Change

About NBIX

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.
More

Webull offers Neurocrine Biosciences, Inc. (NBIX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.